Under the Paperwork Reduction Act of 1995, no persons are required to respon

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09843051				
Filing Date		2006-04-26				
First Named Inventor Martin		n T, Gerber				
Art Unit		3762				
Examiner Name	G.Ev	vanisko				
Attorney Docket Number		P-8436.03				

					U.S.I	PATENTS			Remove		
Examiner Cite Initial*		Patent Number	Kind Code <sup>1</sup>			Name of Pate of cited Docu	Pages,Columns,Line Relevant Passages Figures Appear				
	1	4379462		1983-0	4-12	Borkan					
	2 6055456 2000-04-25		4-25	Gerber							
	3	5562722		1996-0	8-10	Racz et al					
If you wisl	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Cite Initial* No Publication Number Kind Code* Date					tion	Name of Patentee or Applicant Re			ages,Columns,Lines where elevant Passages or Relevant gures Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ada	d buttor	. Add		_
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or	Pages,Colu where Rele Passages of Figures App	vant or Relevant	TS
	1	862925	EP			2004-01-09					

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09843051			
Filing Date		2006-04-26			
First Named Inventor	Marti	n T. Gerber			
Art Unit		3762			
Examiner Name	G.Ev	ranisko			
Attorney Docket Number		P-8436 03			

If you wish	h to a	dd add	Iditional Foreign Patent Document citation information please click the Add button Add						
			NON-PATENT LITERATURE DOCUMENTS Remove						
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter (look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	1								
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

See Kink Codes of USPTO Planto Documents at year, USPTO, QCV or MPEP 901.04. \* Exter office in all issued the document, by the two letter code (WIPO Standard ST3.). \* For Legarance parted consument, the includator on the pase of the reign or the Engeror must proceed be resist in number for be parted rocument. \* Mind of coursent by the appropriate symbots as indicated on the document under WIPO Standard ST.168 possible. \* Applicant is to place a check man, here if English througher strateform a standard.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09843051				
Filing Date			2006-04-26				
	First Named Inventor Martin		n T. Gerber				
	Art Unit		3762				
	Examiner Name G. Ev		ranisko				
	Attorney Docket Number		P-8436.03				

48 935

#### CERTIFICATION STATEMENT

Please see	37	CFR .	1 97	and	1 02	to	make t	ha	annror	rioto	cal	lanti	nn/	۱۵	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information discourse statement was known to [2] any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c) and the contraction of the contraction

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Anna M Nelson

None

Name/Print

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.			
Signature	/Anna M. Nelson/	Date (YYYY-MM-DD)	2006-05-03

Registration Number

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operament of Commence, P. 0. Box 1450, Alexandris, V.2.2311-4450. DN OTS CEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. (2)(2)(2) farmishing of the information solicide to is columbary, and (3) the primoral pursues for which the information is used by the U.S. Patient and Trademan (Office is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested requirement of the patient of the patient application or patient. If you do not furnish the requested requirement of the patient application or patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C.552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- . A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fied in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application part to published application, an application part to put to published application, an application.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.